For example, enoblituzumab, a B7-H3–targeting Ab, has shown potential in early clinical trials (NCT02923180) as a neoadjuvant immunotherapeutic option for patients with high-grade prostate cancer (15). This evidence concerns the gene CD276 and prostate cancer.